menu
    • menu
    [{"orgOrder":0,"company":"Unnatural Products","sponsor":"Argenx","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Collaboration","leadProduct":"Inapplicable","moa":"||Undisclosed","graph1":"Technology","graph2":"Discovery Platform","graph3":"Unnatural Products","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Unnatural Products \/ Argenx","highestDevelopmentStatusID":"3","companyTruncated":"Unnatural Products \/ Argenx"},{"orgOrder":0,"company":"Unnatural Products","sponsor":"BridgeBio Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2024","type":"Agreement","leadProduct":"Inapplicable","moa":"||Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Unnatural Products","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Unnatural Products \/ BridgeBio Pharma","highestDevelopmentStatusID":"3","companyTruncated":"Unnatural Products \/ BridgeBio Pharma"}]

    Find Clinical Drug Pipeline Developments & Deals by Unnatural Products

    Menu

    Unnatural Products

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Unnatural Products

                            U.S.A arrow
                            EPSC
                            Not Confirmed

                            Unnatural Products

                            U.S.A arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed,Inapplicable

                            Therapeutic Area : Technology

                            Study Phase : Discovery Platform

                            Sponsor : Argenx

                            Deal Size : $1,500.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Unnatural Products Announces Multi-Target Collaboration with argenx

                            Details : The collaboration aims to discover and develop oral macrocyclic peptide drugs targeting traditionally “undruggable,” disease targets, using UNP’s proprietary drug discovery platform.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            July 01, 2025

                            Lead Product(s) : Undisclosed,Inapplicable

                            Therapeutic Area : Technology

                            Highest Development Status : Discovery Platform

                            Sponsor : Argenx

                            Deal Size : $1,500.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Unnatural Products

                            U.S.A arrow
                            EPSC
                            Not Confirmed

                            Unnatural Products

                            U.S.A arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Macrocyclic Peptide,Inapplicable

                            Therapeutic Area : Oncology

                            Study Phase : Discovery Platform

                            Sponsor : BridgeBio Pharma

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Unnatural & BridgeBio Partner on Macrocyclic Therapeutics for Rare Diseases

                            Details : Under the terms of the agreement, UNP assumed responsibility for R&D, and BridgeBio will assume the further development of the macrocyclic peptide candidates for rare diseases and oncology.

                            Product Name : Undisclosed

                            Product Type : Peptide

                            Upfront Cash : Undisclosed

                            March 12, 2024

                            Lead Product(s) : Macrocyclic Peptide,Inapplicable

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery Platform

                            Sponsor : BridgeBio Pharma

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth